<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578015</url>
  </required_header>
  <id_info>
    <org_study_id>2020H0476</org_study_id>
    <nct_id>NCT04578015</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Treatment of Bacterial Vaginosis</brief_title>
  <official_title>A Randomized Controlled Trial of Treatment of Bacterial Vaginosis in Late Third Trimester to Prevent Maternal Peripartum Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, placebo controlled, multi-center randomized trial of 482 pregnant&#xD;
      women who are diagnosed with Bacterial Vaginosis (BV) in the late 3rd trimester (&gt;34 weeks).&#xD;
      During routine clinic visit after 34 weeks, prospective patients will be counseled about the&#xD;
      study. Patients who agree to be enrolled, will sign informed consent. Following enrollment,&#xD;
      patients will be screened for BV. Those patients who are BV positive by clinical diagnosis,&#xD;
      will be randomized to receive either metronidazole 500 mg BID orally for 7 days or&#xD;
      identically appearing placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating Composite of chorioamnionitis, postpartum endometritis, SSI, wound infection, or other post-cesarean infections (occurring within 6 weeks after delivery)</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of individual infections.</measure>
    <time_frame>At the time of admission for labor trough study completion, an average of 18 months</time_frame>
    <description>Chorioamnionitis, endometritis, wound infection (including necrotizing fascitis), other infections including abscess, septic thrombosis, pneumonia, pyelonephritis and breast infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of maternal death</measure>
    <time_frame>After delivery through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of Puerperal fever.</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>Temperature &gt; 100.4 F at least twice 30 minutes apart, or once with the use of antipyretic, or ≥101 F once.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of Use of resources.</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>Hospital stay, postpartum clinic or emergency room visit within 4 weeks of delivery, need for imaging or other invasive procedures, postpartum antibiotic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of adverse events</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis), GI symptoms (nausea, vomiting, diarrhea, constipation, ileus, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of suspected sepsis for newborns</measure>
    <time_frame>Within 7 days of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of confirmed sepsis for newborns</measure>
    <time_frame>Within 7 days of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of Newborn Intensive Care Unit (NICU) admission and duration</measure>
    <time_frame>After delivery through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of Neonatal morbidities</measure>
    <time_frame>After delivery through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">482</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Metronidazole 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days</description>
    <arm_group_label>Metronidazole 500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in this arm will receive placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women 18 to ≤50 years with the ability to give informed consent.&#xD;
&#xD;
          -  Patients expected to have a vaginal delivery with no obstetric contraindication for&#xD;
             vaginal delivery at time of screening.&#xD;
&#xD;
          -  Diagnosed with bacterial BV per Amsel criteria at time of screening in clinic.&#xD;
&#xD;
          -  Gestational age ≥ 35 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Plan for elective cesarean delivery&#xD;
&#xD;
          -  Allergy or contraindications to metronidazole&#xD;
&#xD;
          -  Receipt of metronidazole or clindamycin on admission for delivery for other&#xD;
             indications.&#xD;
&#xD;
          -  Hemodialysis&#xD;
&#xD;
          -  Severe liver dysfunction&#xD;
&#xD;
          -  Patient reports BV to nurse or clinician provider at current clinic visit or has been&#xD;
             treated for BV within the past 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kartik Venkatesh, MD,PhD</last_name>
    <phone>614-293-2222</phone>
    <email>Kartik.Venkatesh@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmoud Abdelwahab, MD</last_name>
    <phone>614-293-8045</phone>
    <email>Mahmoud.Abdelwahab@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kartik Venkatesh, MD,PhD</last_name>
      <phone>614-293-2222</phone>
      <email>Kartik.Venkatesh@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mahmoud Abdelwahab, MD</last_name>
      <phone>614-293-8045</phone>
      <email>Mahmoud.Abdelwahab@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Abdelwahab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maged Costantine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaye Snow, RNC-OB</last_name>
      <phone>937-208-2411</phone>
      <email>eksnow@premierhealth.com</email>
    </contact>
    <investigator>
      <last_name>Samantha Wiegand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kartik K Venkatesh</investigator_full_name>
    <investigator_title>MD, PhD Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Bacterial Vaginoses</keyword>
  <keyword>Cesarean delivery</keyword>
  <keyword>Surgical site infection</keyword>
  <keyword>Endometritis</keyword>
  <keyword>Infection</keyword>
  <keyword>Vaginitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

